CYTOKINETICS, INCORPORATED Cash and Cash Equivalents, Period Increase (Decrease)
CYTOKINETICS, INCORPORATED (CYTK) reported Cash and Cash Equivalents, Period Increase (Decrease) of -$10.20 million for the 3-month period ending 2018-03-31, per its 10-Q filed 2018-05-10.
Discontinued › Cash Flow
us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease · last filed 2018-05-10
- CYTOKINETICS, INCORPORATED cash and cash equivalents, period increase (decrease) for the quarter ending 2018-03-31 was -$10.20M.
- CYTOKINETICS, INCORPORATED cash and cash equivalents, period increase (decrease) for the quarter ending 2017-12-31 was $8.89M, a 75.70% decline year-over-year.
- CYTOKINETICS, INCORPORATED cash and cash equivalents, period increase (decrease) for the quarter ending 2017-09-30 was $15.61M, a 505.94% increase year-over-year.
- CYTOKINETICS, INCORPORATED cash and cash equivalents, period increase (decrease) for the quarter ending 2017-06-30 was $51.35M.
- CYTOKINETICS, INCORPORATED cash and cash equivalents, period increase (decrease) for fiscal 2017 was $58.33M, a 3144.27% increase from fiscal 2016.
- CYTOKINETICS, INCORPORATED cash and cash equivalents, period increase (decrease) for fiscal 2016 was $1.80M, a 95.99% decline from fiscal 2015.
- CYTOKINETICS, INCORPORATED cash and cash equivalents, period increase (decrease) for fiscal 2015 was $44.86M, a 78603.51% increase from fiscal 2014.
- CYTOKINETICS, INCORPORATED cash and cash equivalents, period increase (decrease) for fiscal 2014 was $57.00K, a 98.91% decline from fiscal 2013.
| Period end | Cash and Cash Equivalents, Period Increase (Decrease) 3 month | Cash and Cash Equivalents, Period Increase (Decrease) 6 month | Cash and Cash Equivalents, Period Increase (Decrease) 9 month | Cash and Cash Equivalents, Period Increase (Decrease) 12 month | Cash and Cash Equivalents, Period Increase (Decrease) 167 month | Cash and Cash Equivalents, Period Increase (Decrease) 170 month | Cash and Cash Equivalents, Period Increase (Decrease) 173 month | Cash and Cash Equivalents, Period Increase (Decrease) 176 month | Cash and Cash Equivalents, Period Increase (Decrease) 179 month | Cash and Cash Equivalents, Period Increase (Decrease) 182 month | Cash and Cash Equivalents, Period Increase (Decrease) 185 month | Cash and Cash Equivalents, Period Increase (Decrease) 188 month | Cash and Cash Equivalents, Period Increase (Decrease) 191 month | Cash and Cash Equivalents, Period Increase (Decrease) 194 month |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2018-03-31 | -$10.20M 10-Q · filed 2018-05-10 | -$1.31M derived: sum of 2 quarters · filed 2018-05-10 | $14.30M derived: sum of 3 quarters · filed 2018-05-10 | $65.65M derived: sum of 4 quarters · filed 2018-05-10 | ||||||||||
| 2017-12-31 | $8.89M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-05 | $24.50M derived: sum of 2 quarters · filed 2018-03-05 | $75.84M derived: sum of 3 quarters · filed 2018-03-05 | $58.33M 10-K · filed 2018-03-05 | ||||||||||
| 2017-09-30 | $15.61M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-03 | $66.96M derived: sum of 2 quarters · filed 2017-11-03 | $49.45M 10-Q · filed 2017-11-03 | $86.02M derived: sum of 4 quarters · filed 2018-05-10 | ||||||||||
| 2017-06-30 | $51.35M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-04 | $33.84M 10-Q · filed 2017-08-04 | $70.41M derived: sum of 3 quarters · filed 2018-05-10 | $72.99M derived: sum of 4 quarters · filed 2018-05-10 | ||||||||||
| 2017-03-31 | -$17.51M 10-Q · filed 2018-05-10 | $19.06M derived: sum of 2 quarters · filed 2018-05-10 | $21.64M derived: sum of 3 quarters · filed 2018-05-10 | $7.09M derived: sum of 4 quarters · filed 2018-05-10 | ||||||||||
| 2016-12-31 | $36.57M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-05 | $39.15M derived: sum of 2 quarters · filed 2018-03-05 | $24.61M derived: sum of 3 quarters · filed 2018-03-05 | $1.80M 10-K · filed 2018-03-05 | ||||||||||
| 2016-09-30 | $2.58M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-03 | -$11.97M derived: sum of 2 quarters · filed 2017-11-03 | -$34.78M 10-Q · filed 2017-11-03 | $4.34M derived: sum of 4 quarters · filed 2018-03-05 | ||||||||||
| 2016-06-30 | -$14.54M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-04 | -$37.35M 10-Q · filed 2017-08-04 | $1.76M derived: sum of 3 quarters · filed 2018-03-05 | $2.88M derived: sum of 4 quarters · filed 2018-03-05 | ||||||||||
| 2016-03-31 | -$22.81M 10-Q · filed 2017-05-04 | $16.31M derived: sum of 2 quarters · filed 2018-03-05 | $17.43M derived: sum of 3 quarters · filed 2018-03-05 | $19.72M derived: sum of 4 quarters · filed 2018-03-05 | ||||||||||
| 2015-12-31 | $39.11M derived: 10-K 12 month − 10-Q/A 9 month · filed 2018-03-05 | $40.24M derived: sum of 2 quarters · filed 2018-03-05 | $42.53M derived: sum of 3 quarters · filed 2018-03-05 | $44.86M 10-K · filed 2018-03-05 | ||||||||||
| 2015-09-30 | $1.12M derived: 10-Q/A 9 month − 10-Q 6 month · filed 2016-12-15 | $3.42M derived: sum of 2 quarters · filed 2016-12-15 | $5.75M 10-Q/A · filed 2016-12-15 | $13.05M derived: sum of 4 quarters · filed 2017-03-06 | ||||||||||
| 2015-06-30 | $2.29M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-04 | $4.62M 10-Q · filed 2016-08-04 | $11.93M derived: sum of 3 quarters · filed 2017-03-06 | $12.48M derived: sum of 4 quarters · filed 2017-03-06 | ||||||||||
| 2015-03-31 | $2.33M 10-Q · filed 2016-05-05 | $9.64M derived: sum of 2 quarters · filed 2017-03-06 | $10.19M derived: sum of 3 quarters · filed 2017-03-06 | $9.29M derived: sum of 4 quarters · filed 2017-03-06 | ||||||||||
| 2014-12-31 | $7.31M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-06 | $7.86M derived: sum of 2 quarters · filed 2017-03-06 | $6.96M derived: sum of 3 quarters · filed 2017-03-06 | $57.00K 10-K · filed 2017-03-06 | ||||||||||
| 2014-09-30 | $552.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-05 | -$349.00K derived: sum of 2 quarters · filed 2015-11-05 | -$7.25M 10-Q · filed 2015-11-05 | -$6.35M derived: sum of 4 quarters · filed 2016-03-03 | ||||||||||
| 2014-06-30 | -$901.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-05 | -$7.80M 10-Q · filed 2015-08-05 | -$6.90M derived: sum of 3 quarters · filed 2016-03-03 | -$4.70M derived: sum of 4 quarters · filed 2016-03-03 | ||||||||||
| 2014-03-31 | -$6.90M 10-Q · filed 2015-05-04 | -$6.00M derived: sum of 2 quarters · filed 2016-03-03 | -$3.80M derived: sum of 3 quarters · filed 2016-03-03 | $96.00K derived: sum of 4 quarters · filed 2016-03-03 | ||||||||||
| 2013-12-31 | $900.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-03 | $3.10M derived: sum of 2 quarters · filed 2016-03-03 | $7.00M derived: sum of 3 quarters · filed 2016-03-03 | $5.25M 10-K · filed 2016-03-03 | ||||||||||
| 2013-09-30 | $2.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-06 | $6.10M derived: sum of 2 quarters · filed 2014-11-06 | $4.35M 10-Q · filed 2014-11-06 | $3.87M derived: sum of 4 quarters · filed 2015-03-06 | $19.26M 10-Q · filed 2013-11-06 | |||||||||
| 2013-06-30 | $3.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-07 | $2.15M 10-Q · filed 2014-08-07 | $1.67M derived: sum of 3 quarters · filed 2015-03-06 | -$46.60M derived: sum of 4 quarters · filed 2015-03-06 | $17.06M 10-Q · filed 2013-08-07 | |||||||||
| 2013-03-31 | -$1.75M 10-Q · filed 2014-05-07 | -$2.23M derived: sum of 2 quarters · filed 2015-03-06 | -$50.49M derived: sum of 3 quarters · filed 2015-03-06 | -$4.66M derived: sum of 4 quarters · filed 2015-03-06 | $13.16M 10-Q · filed 2013-05-08 | |||||||||
| 2012-12-31 | -$483.00K derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-06 | -$48.75M derived: sum of 2 quarters · filed 2015-03-06 | -$2.91M derived: sum of 3 quarters · filed 2015-03-06 | -$3.93M 10-K · filed 2015-03-06 | $14.91M 10-K · filed 2013-03-15 | |||||||||
| 2012-09-30 | -$48.26M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-06 | -$2.42M derived: sum of 2 quarters · filed 2013-11-06 | -$3.44M 10-Q · filed 2013-11-06 | -$3.20M derived: sum of 4 quarters · filed 2014-03-07 | $15.39M 10-Q · filed 2012-11-07 | |||||||||
| 2012-06-30 | $45.84M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-07 | $44.82M 10-Q · filed 2013-08-07 | $45.06M derived: sum of 3 quarters · filed 2014-03-07 | $39.88M derived: sum of 4 quarters · filed 2014-03-07 | $63.65M 10-Q · filed 2012-08-06 | |||||||||
| 2012-03-31 | -$1.02M 10-Q · filed 2013-05-08 | -$776.00K derived: sum of 2 quarters · filed 2014-03-07 | -$5.95M derived: sum of 3 quarters · filed 2014-03-07 | $2.36M derived: sum of 4 quarters · filed 2014-03-07 | $17.82M 10-Q · filed 2012-05-04 | |||||||||
| 2011-12-31 | $242.00K derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-07 | -$4.94M derived: sum of 2 quarters · filed 2014-03-07 | $3.38M derived: sum of 3 quarters · filed 2014-03-07 | $1.32M 10-K · filed 2014-03-07 | $18.83M 10-K · filed 2012-03-13 | |||||||||
| 2011-09-30 | -$5.18M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-07 | $3.14M derived: sum of 2 quarters · filed 2012-11-07 | $1.08M 10-Q · filed 2012-11-07 | -$11.85M derived: sum of 4 quarters · filed 2013-03-15 | $18.59M 10-Q · filed 2011-11-04 | |||||||||
| 2011-06-30 | $8.32M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-06 | $6.25M 10-Q · filed 2012-08-06 | -$6.67M derived: sum of 3 quarters · filed 2013-03-15 | $5.40M derived: sum of 4 quarters · filed 2013-03-15 | $23.77M 10-Q · filed 2011-08-04 | |||||||||
| 2011-03-31 | -$2.06M 10-Q · filed 2012-05-04 | -$14.99M derived: sum of 2 quarters · filed 2013-03-15 | -$2.91M derived: sum of 3 quarters · filed 2013-03-15 | |||||||||||
| 2010-12-31 | -$12.93M derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-15 | -$851.00K derived: sum of 2 quarters · filed 2013-03-15 | -$8.05M 10-K · filed 2013-03-15 | |||||||||||
| 2010-09-30 | $12.07M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-04 | $4.88M 10-Q · filed 2011-11-04 | ||||||||||||
| 2010-06-30 | -$7.20M 10-Q · filed 2011-08-04 | |||||||||||||
| 2009-12-31 | -$16.26M 10-K · filed 2012-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 |